000220.KS
Yuyu Pharma, Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 3,805.00
−1.93%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 144.4B | 140.9B | 133.1B | 137.2B | 138.9B |
| Cost of Revenue | 89.3B | 86.9B | 81.4B | 88.7B | 85.6B |
| Gross Profit | 55.1B | 53.9B | 51.7B | 48.5B | 53.3B |
| Operating Expenses | |||||
| R&D Expense | 3.6B | 3.6B | 2.8B | 7.2B | 8.6B |
| SG&A Expense | 23.8B | 19.6B | 17.9B | 15.9B | 20.0B |
| General & Admin Expense | 1.8B | 2.5B | 2.7B | 4.2B | 5.0B |
| Selling & Marketing Expense | 12.7B | 17.1B | 15.2B | 11.7B | 15.0B |
| Other Expenses | 14.5B | 19.7B | 19.3B | 25.4B | 25.3B |
| Total Operating Expenses | 41.9B | 42.9B | 40.0B | 47.3B | 53.9B |
| Cost and Expenses | 131.4B | 129.9B | 121.4B | 136.8B | 139.5B |
| Operating Income (EBIT) | 13.2B | 11.0B | 11.7B | 364.5M | 691.7M |
| Non-Operating | |||||
| Interest Income | 3.0B | 3.3B | 1.0B | 896.7M | 561.7M |
| Interest Expense | 5.1B | 5.6B | 3.2B | 2.6B | 2.6B |
| Net Interest Income | (2.0B) | (2.3B) | (2.2B) | (1.7B) | (2.0B) |
| Other Non-Op Income/Expense | (36.1M) | (1.5B) | (1.7B) | (5.8B) | (3.2B) |
| Non-Operating Income (excl Interest) | (1.3B) | — | (1.5B) | 1.1B | 637.5M |
| EBT (Pre-Tax Income) | 13.1B | 9.5B | 10.0B | (5.4B) | (3.8B) |
| Income Tax Expense | 695.2M | 366.0M | (304.7M) | 98.4M | 615.0M |
| Bottom Line | |||||
| Net Income | 12.5B | 8.2B | 8.7B | (7.2B) | (4.4B) |
| Earnings from Cont. Ops | 12.4B | 9.1B | 10.3B | (5.5B) | (4.4B) |
| Earnings from Discont. Ops | — | — | — | (2.8K) | (395.1M) |
| Bottom Line Net Income | 12.1B | 7.8B | 7.6B | (7.2B) | (6.0B) |
| Per Share | |||||
| Basic EPS | ₩746 | ₩492 | ₩468 | (₩441) | (₩267) |
| Diluted EPS | ₩621 | ₩463 | ₩451 | (₩441) | (₩267) |
| Revenue Per Share | ₩9,168 | ₩8,492 | ₩8,228 | ₩8,434 | ₩8,376 |
| Shares | |||||
| Basic Shares Outstanding | 15.7M | 16.6M | 16.2M | 16.3M | 16.6M |
| Diluted Shares Outstanding | 19.8M | 16.8M | 16.8M | 16.3M | 16.6M |
| Profitability Metrics | |||||
| EBITDA | 9.6B | 16.6B | 18.9B | 4.9B | 3.4B |
| D&A | 5.7B | 5.6B | 5.7B | 5.6B | 5.0B |
| EBIT | 3.9B | 11.0B | 13.2B | (748.9M) | (1.2B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026